Skip to main content

Select Drug Profiles

Select Drug Profiles

Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors

Lisa A. Raedler, PhD, RPh

Select Drug Profiles

Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation

Select Drug Profiles

Xospata (Gilteritinib) First Drug Approved as Monotherapy for Adults with Relapsed or Refractory Acute Myeloid Leukemia with FLT3 Mutation

Lisa A. Raedler, PhD, RPh

Select Drug Profiles

Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer

Select Drug Profiles

Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation

Lisa A. Raedler, PhD, RPh

FDA Approvals, In the News, Select Drug Profiles

FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma

Select Drug Profiles

Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy

Select Drug Profiles

Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation

Lisa A. Raedler, PhD, RPh

FDA Approvals, In the News, Select Drug Profiles

Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation

Breast Cancer, FDA Approvals, In the News, Select Drug Profiles

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

11
12
13
14
15
16
17

Page 14 of 20
Results 131 - 140 of 200